Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 12 May 2017

German Biotech Raises €15M to Treat Heart Failure with Non-coding RNA

Cardior Pharmaceuticals will use the funds to develop an innovative technology based on non-coding RNAs involved in cardiac remodeling. Founded less than a year ago, Cardior Pharmaceuticals is dedicated to developing a novel technology to predict and treat heart failure. In such a short timeframe, the German biotech has managed to attract some of the best […]

May 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Celyad heart failure cell therapy C Cure

News and Trends 11 May 2017

Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy

Celyad has received Fast Track Designation from the FDA for C-Cure, a cell therapy aimed to treat heart failure with the patient’s own stem cells. Celyad is confident that the announcement of Fast Track Designation from the FDA will help it accelerate the search for a partner to develop C-Cure, a cell therapy for ischemic […]

May 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 10 May 2017

Experts say the Microbiome could overtake Genetics as the Next Big Thing

Yesterday, a panel of experts at BioTrinity discussed the huge possibilities offered by the young microbiome field, which could soon overtake genetics. Scientists and investors worldwide are starting to turn to the microbiome, which many believe hold the key to human health. The microorganisms that live in us and on us have shown to play […]

May 10, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 May 2017

AI-Based Drug Discovery Biotech is Recruited by Sanofi in €250M Deal

As part of the deal with Sanofi, Exscientia will tackle the discovery and design of new bispecific drugs using artificial intelligence algorithms. Exscientia, based in Scotland, is a company that uses artificial intelligence (AI) to develop new drugs faster. Its edge-cutting technology has caught the attention of Sanofi, which is offering Exscientia research funding and […]

May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 9 May 2017

Scottish Shark Antibodies have caught Amgen’s Eye

Elasmogen and its partner Feldan Therapeutics have signed a research agreement with Amgen to develop shark-inspired antibodies delivered intracellularly. Elasmogen, based in Aberdeen, Scotland, develops soloMER‘s, which are the smallest naturally-occurring antibody binding domains. “They are remarkably stable,” Caroline Barelle told me this morning at BioTrinity in London. “They can survive extreme pH and temperatures […]

May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 May 2017

French Researchers Discover a Target to Prevent Zika Birth Defects

Researchers from the Institut Pasteur and the Inserm have identified a protein target that, when overexpressed, can block Zika infections. The recent Zika epidemics in the Pacific and South America has led the World Health Organization (WHO) to declare a state of global emergency. One of the biggest concerns at the moment is that the […]

May 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 6 May 2017

Color Patterns in the Clothes of the Future will be Made by Bacteria

Natsai Audrey Chieza is an artist and researcher exploring the integration of life into the manufacturing of the materials of the future. Natsai Audrey Chieza wants to break with the current paradigm of fashion design and textile production with the help of microbiology. Her research focuses on developing bacterial biopigments for textiles to replace the […]

May 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 May 2017

Forget Chemical Synthesis, Yeast can Now Synthesize Complex Antibiotics

A new study presents a novel synthetic biology approach for antibiotic synthesis in yeast that could tackle the huge challenge of antibiotic resistance. Scientists at Imperial College London have hacked their way into introducing complex biosynthesis pathways in the baker’s yeast Saccharomyces cerevisiae. In particular, they focused on the production of non-ribosomal peptides (Nrp), a group of […]

May 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 May 2017

Solid First-in-Human Results from Vaccine against Birth Defects

Hookipa has presented positive data from its first Phase I trial testing its vaccine technology against human cytomegalovirus (hCMV) infections. Hookipa, one of the top 10 biotechs we’re closely following this year, is developing a viral vaccine platform that has attracted big investments from both the private and the public sector. The company just announced […]

May 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

vivet therapeutics gene therapy fundraising

News and Trends 4 May 2017

French Gene Therapy Biotech Raises a Huge €37.5M in Series A

Vivet Therapeutics has raised a huge €37.5M in Series A to help bring a new gene therapy technology for rare liver diseases to the clinic. Vivet Therapeutics has managed to attract some of the hottest biotech investors in Europe in its Series A. Led by Novartis Venture Fund and Columbus Venture Partners, and also counting […]

May 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 May 2017

French Biotech gets a Second Opportunity to Fight Liver Fibrosis

Genkyotex, a French biotech with an eye on NASH, has received FDA approval to initiate a Phase II trial in primary biliary cholangitis. Genkyotex’s lead candidate, GKT831, failed to prove its efficacy in a Phase II trial for diabetic nephropathy a couple of years ago. Now, the company is taking a second shot by targeting liver […]

May 3, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 May 2017

French HIV Cure Reduces Viral Reservoirs for the First Time Ever

Abivax has announced results from a Phase IIa trial that reveal the first proof in human of viral load reduction of hidden HIV reservoirs. Abivax is developing a functional HIV cure that, unlike current antiretroviral therapy (ART), could completely eliminate the virus and prevent it from coming back when the treatment is stopped. Results from a Phase IIa […]

May 2, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us